STUDY AIM The purpose of the study is to evaluate whether kynurenine is directly connected to ME/CFS patient symptom severity. LEAD INVESTIGATORS Jonas Bergquist, MD, PhD, Prof, Director ScD Kumari Ubhayasekhera, PhD Sandy Abujrais. PhD Student further details here https://www.omf.ngo/2020/08/05/kynurenine-trial-in-me-cfs/
Nice. I was under the impression that Stanford would conduct the kynurenine trial and that Berquist et al. would be responsible for the pyridostigmine one, but anyway, I feel more excited about this one. At least this is something new I haven't seen previously attempted unlike with Mestinon.
Bit more from Robert Phair - haven't read them yet. https://forums.phoenixrising.me/thr...in-dosed-in-the-day.43606/page-2#post-2307414 There's also some stuff on the metabolic trap but it's only available to members.
